BARCELONA — Use of real-time continuous glucose monitoring (rtCGM) can help improve blood glucose control in people with type 1 diabetes whether they use an insulin pump or multiple daily injections (MDI) of insulin, new research suggests.
Three-year data from the Comparison of Different Treatment Modalities for Type 1 Diabetes Including Sensor-Augmented Insulin Regimens (COMISAIR) study were presented here at the European Association for the Study of Diabetes (EASD) 2019 Annual Meeting by Jan Šoupal, MD, PhD, Charles University, Prague, Czech Republic.
The results were simultaneously published in Diabetes Care.
At 3 years — the longest duration of any CGM trial — real-time (not flash) CGM was superior to self-monitored blood glucose (SMBG), or fingerstick, testing at least four times daily in reducing HbA1c in patients using both pumps and MDI, with little difference between the two insulin delivery modalities.
Only the rtCGM group had improvements in time-in-range and reduced time below range. Fewer patients using rtCGM experienced severe hypoglycemic episodes.
This way –> MedScape.com
